Dup15q Syndrome Market Expected to rise, 2032 | Ovid Therapeutics, Takeda, Q-State Biosciences, Radius Health, Zogenix, expected to drive market

The Dup15q Syndrome market growth is driven by factors like increase in the prevalence of Dup15q Syndrome, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Dup15q Syndrome market report [https://www.delveinsight.com/report-store/dup15q-syndrome-market-forecast?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Dup15q Syndrome market size, share, Dup15q Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Dup15q Syndrome market size growth forward.

Some of the key highlights from the Dup15q Syndrome Market Insights Report:

*
According to DelveInsight, the Dup15q Syndrome Market is projected to grow at a strong rate during the forecast period (2023-2032), driven by the introduction of new therapies.

*
In November 2024, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced Phase 1/2 data that supports the Phase 3 Aspire study for GTX-102, its experimental antisense oligonucleotide aimed at treating Angelman syndrome. This data will be showcased at the 2024 Foundation for Angelman Syndrome Therapeutics (FAST) Global Science Summit.

*
Key companies in the Dup15q Syndrome market, including Ovid Therapeutics, Takeda, Q-State Biosciences, Radius Health, and Zogenix, are actively contributing to its development.

Strategise your business goals by understanding market dynamics @ Dup15q Syndrome Market Landscape [https://www.delveinsight.com/sample-request/dup15q-syndrome-market-forecast?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Dup15q Syndrome Overview

Dup15q syndrome is a rare genetic condition caused by the duplication of part of chromosome 15, leading to various developmental challenges. It is characterized by hypotonia (low muscle tone), delays in motor skills, intellectual disability (ID), autism spectrum disorder (ASD), and epilepsy, with infantile spasms being a common type of seizure. The severity of these symptoms can vary depending on the specific genetic duplication and whether it is inherited from the mother or father.

Diagnosis of maternal dup15q syndrome is confirmed by detecting an extra copy of the Prader-Willi/Angelman critical region on chromosome 15q11.2-q13.1. Individuals with dup15q syndrome often show hypotonia in infancy, motor delays, ID, and language delays.

Currently, there is no cure for dup15q syndrome, but symptoms can be managed with treatments like antiepileptic medications, and therapies such as physical, occupational, and speech therapy. Applied behavioral analysis (ABA) therapy is also used to address social skill deficits associated with the syndrome.

Do you know the treatment paradigms for different countries? Download our Dup15q Syndrome Market Sample Report [https://www.delveinsight.com/report-store/dup15q-syndrome-market-forecast?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Dup15q Syndrome Epidemiology Insights

*
In 2021, there were approximately 5,000 diagnosed cases of dup15q syndrome in the United States. According to DelveInsight's projections, this number is anticipated to rise by 2032.

*
In the EU4 and the UK, the total number of prevalent dup15q syndrome cases was around 15,600 in 2021, with expectations for steady growth during the study period.

Dup15q Syndrome Epidemiology Segmentation

DelveInsight's Dup15q Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Dup15q Syndrome historical patient pools and forecasted Dup15q Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Dup15q Syndrome Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

*
Dup15q Syndrome Prevalence

*
Age-Specific Dup15q Syndrome Prevalence

*
Gender-Specific Dup15q Syndrome Prevalence

*
Diagnosed and Treatable Cases of Dup15q Syndrome

Visit for more @ Dup15q Syndrome Epidemiological Insights [https://www.delveinsight.com/sample-request/dup15q-syndrome-market-forecast?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Dup15q Syndrome Market Dynamics

The Dup15q Syndrome drug market is shaped by both driving factors and challenges. On the positive side, growing awareness and understanding of this rare genetic disorder have led to earlier diagnoses and increased demand for treatments. Additionally, advancements in precision medicine and the development of targeted therapies present opportunities to address specific symptoms, such as epilepsy and developmental delays. Collaboration between patient advocacy groups and research organizations has also accelerated progress in Dup15q syndrome research, driving innovation.

However, several obstacles hinder progress in the market. The rarity and diversity of the condition make it difficult to conduct large-scale clinical trials and create standardized treatments. Limited public awareness and delayed diagnoses can also lead to late interventions. Additionally, the high cost of specialized therapies may restrict access for some patients. Overcoming these barriers and expanding research efforts will be crucial for advancing the market and improving the lives of those with Dup15q Syndrome.

Numerous emerging therapies are under development, offering new therapeutic options with innovative mechanisms to treat Dup15q syndrome. Key companies involved in this space include Roche, Takeda, Q-State Biosciences, Ovid Therapeutics, Radius Health, Zogenix, and others.

Dup15q Syndrome Key Companies

*
Ovid Therapeutics

*
Takeda

*
Q-State Biosciences

*
Radius Health

*
Zogenix, and others

For more information, visit Dup15q Syndrome Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/dup15q-syndrome-market-forecast?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Dup15q Syndrome Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Dup15q Syndrome, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Dup15q Syndrome epidemiology in the 7MM

*
Dup15q Syndrome marketed and emerging therapies

*
Dup15q Syndrome companies

*
Dup15q Syndrome market drivers and barriers

Table of Contents:

1 Dup15q Syndrome Market Key Comprehensive Insights

2 Dup15q Syndrome Market Report Introduction

3 Competitive Intelligence Analysis for Dup15q Syndrome

4 Dup15q Syndrome Market Analysis Overview at a Glance

5 Executive Summary of Dup15q Syndrome

6 Dup15q Syndrome Epidemiology and Market Methodology

7 Dup15q Syndrome Epidemiology and Patient Population

8 Dup15q Syndrome Patient Journey

9 Dup15q Syndrome Treatment Algorithm, Dup15q Syndrome Current Treatment, and Medical Practices

10 Key Endpoints in Dup15q Syndrome Clinical Trials

11 Dup15q Syndrome Marketed Therapies

12 Dup15q Syndrome Emerging Therapies

13 Dup15q Syndrome: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Dup15q Syndrome

16 Dup15q Syndrome Market Key Opinion Leaders Reviews

18 Dup15q Syndrome Market Drivers

19 Dup15q Syndrome Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Dup15q Syndrome Epidemiology 2032

DelveInsight's "Dup15q Syndrome - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Dup15q Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Dup15q Syndrome Pipeline 2024

"Dup15q Syndrome Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Dup15q Syndrome market. A detailed picture of the Dup15q Syndrome pipeline landscape is provided, which includes the disease overview and Dup15q Syndrome treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dup15q-syndrome-market-expected-to-rise-2032-ovid-therapeutics-takeda-qstate-biosciences-radius-health-zogenix-expected-to-drive-market]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.